CELL THERAPEUTICS, INC.
Cell Therapeutics, Inc. Announces Pricing of Upsized Public...
Cell Therapeutics, Inc. Announces Pricing of Upsized Public Offering
of 9,000,000 Shares of Common Stock
SEATTLE, July 28/PRNewswire/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; Nuovo Mercato) today announced the pricing of the
underwritten public offering of 9,000,000 shares of its common stock
at a public offering price of USD $4.75 per share. These shares were
sold under an existing shelf registration statement. The offering was
increased by 1,000,000 shares over the proposed offering announced on
July 14, 2004. In connection with this offering, CTI has granted the
underwriters an option to purchase up to 1,350,000 additional shares
to cover over-allotments. All shares are being sold by CTI.
UBS Securities LLC and CIBC World Markets are acting as joint
book-running managers in this offering. WR Hambrecht + Co, LLC,
Delafield Hambrecht, Inc. and Punk, Ziegel & Company, L.P. are acting
as co-managers. The final prospectus is available from UBS Securities
LLC, Attention: Prospectus Department, 299 Park Avenue, New York, NY
10171, phone number: 212-821-3884, or from CIBC World Markets by fax:
212-667-6136 or email: useprospectus@us.cibc.com.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company
committed to developing an integrated portfolio of oncology products
aimed at making cancer more treatable. For additional information,
please visit www.cticseattle.com.
Web site: http://www.cticseattle.com
Source: Cell Therapeutics, Inc.
CONTACT: investors, Leah Grant of Cell Therapeutics, Inc.,
+1-206-282-7100, or fax, +1-206-272-4010, or invest@ctiseattle.com, or
www.cticseattle.com/investors.htm, or Karl Hanks of Cell Therapeutics,
Inc. (Europe), +39-026-103-5807, or fax, +39-026-103-5601, or
karl.hanks@ctimilano.com
van bovenstaand bericht.
28 jul 04 09:41